Literature DB >> 20426710

Amyloidosis and POEMS syndrome.

Cheng E Chee1, Angela Dispenzieri, Morie A Gertz.   

Abstract

IMPORTANCE OF THE FIELD: Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. AREAS COVERED IN THIS REVIEW: Stem-cell transplantation and novel agents have widened the chemotherapy alternatives available in these disorders and combinations of novel agents with high-dose therapy further improve treatment options. This review covers the main areas of debate in the optimal treatment amyloidosis and POEMS patients, focusing on the implications for everyday clinical practice and management strategies published in the past 36 months. WHAT THE READER WILL GAIN: Insights into treatment strategies are provided in the review. Keys to early recognition of the syndromes are reviewed. TAKE-HOME MESSAGE: With early diagnosis most patients are therapy candidates. New agents and new application of stem-cell transplantation have dramatically improved outcomes for these previously uniformly poor prognosis disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20426710      PMCID: PMC2874109          DOI: 10.1517/14656561003769874

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  79 in total

1.  Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

Authors:  David C Seldin; Jennifer J Anderson; Martha Skinner; Karim Malek; Daniel G Wright; Karen Quillen; Kathleen Finn; Betul Oran; Vaishali Sanchorawala
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

2.  Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.

Authors:  Morie A Gertz; Martha Q Lacy; John A Lust; Philip R Greipp; Thomas E Witzig; Robert A Kyle
Journal:  Haematologica       Date:  2008-07-18       Impact factor: 9.941

3.  Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone.

Authors:  D Lebovic; J Hoffman; B M Levine; H Hassoun; H Landau; Y Goldsmith; M S Maurer; R M Steingart; A D Cohen; R L Comenzo
Journal:  Br J Haematol       Date:  2008-08-04       Impact factor: 6.998

4.  Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture.

Authors:  Karin Sörgjerd; Therése Klingstedt; Mikael Lindgren; Katarina Kågedal; Per Hammarström
Journal:  Biochem Biophys Res Commun       Date:  2008-11-05       Impact factor: 3.575

5.  Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome.

Authors:  Daijiro Abe; Chiaki Nakaseko; Masahiro Takeuchi; Hiroaki Tanaka; Chikako Ohwada; Emiko Sakaida; Yusuke Takeda; Kayo Oda; Shinichi Ozawa; Naomi Shimizu; Shinichi Masuda; Ryuko Cho; Miki Nishimura; Sonoko Misawa; Satoshi Kuwabara; Yasushi Saito
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

6.  Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Authors:  Vaishali Sanchorawala; Daniel G Wright; Michael Rosenzweig; Kathleen T Finn; Salli Fennessey; Jerome B Zeldis; Martha Skinner; David C Seldin
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

Review 7.  The potential of proteasome inhibitors in cancer therapy.

Authors:  Jan Sterz; Ivana von Metzler; Jens-Claus Hahne; Britta Lamottke; Jessica Rademacher; Ulrike Heider; Evangelos Terpos; Orhan Sezer
Journal:  Expert Opin Investig Drugs       Date:  2008-06       Impact factor: 6.206

Review 8.  Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.

Authors:  Satoshi Kuwabara; Angela Dispenzieri; Kimiyoshi Arimura; Sonoko Misawa
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

9.  Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome.

Authors:  S Kuwabara; S Misawa; K Kanai; Y Suzuki; Y Kikkawa; S Sawai; T Hattori; M Nishimura; C Nakaseko
Journal:  Neurology       Date:  2008-10-01       Impact factor: 9.910

10.  Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.

Authors:  S Kuwabara; S Misawa; K Kanai; S Sawai; T Hattori; M Nishimura; C Nakaseko
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-05-09       Impact factor: 10.154

View more
  5 in total

Review 1.  Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma.

Authors:  Motohiro Shindo; Kazuya Sato; Masayo Yamamoto; Yasumichi Toki; Mayumi Hatayama; Satoshi Ito; Kazuhiko Ichiki; Naoka Okamura; Takaaki Hosoki; Katsuya Ikuta; Junki Inamura; Shinji Watanabe; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2011-05-07       Impact factor: 2.490

2.  POEMS Syndrome: A Report of 14 Cases and Review of the Literature.

Authors:  Zong Fei Ji; Dan Ying Zhang; Shu Qiang Weng; Xi Zhong Shen; Hou Yu Liu; Ling Dong
Journal:  ISRN Gastroenterol       Date:  2012-04-01

Review 3.  What is known on angiogenesis-related rare diseases? A systematic review of literature.

Authors:  Luis Rodríguez-Caso; Armando Reyes-Palomares; Francisca Sánchez-Jiménez; Ana R Quesada; Miguel Ángel Medina
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

4.  POEMS syndrome causing left ventricular hypertrophy, myocardial dysfunction, and pericardial effusion: a case report.

Authors:  Shanshan Wang; Xuejie Wu; Hui Li
Journal:  Eur Heart J Case Rep       Date:  2021-12-16

5.  POEMS Syndrome with Biclonal Gammopathy and Renal Involvement.

Authors:  Kohei Inoue; Kei Nagai; Tsuyoshi Tsukada; Mamiko Iwase; Akiko Sakata; Atsushi Ueda; Kunihiro Yamagata
Journal:  Intern Med       Date:  2022-03-12       Impact factor: 1.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.